Bryce, A. H., McDermott, R. S., Piulats, J. M., Reaume, M. N., Ostler, P. J., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nole, F., Staffurth, J. N., Abida, W., Caunt, L., Despain, D., Ryan, C. J., Fizazi, K., Chowdhury, S. (2025). Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.155